TB-500
TB-500 is a peptide, indexed here under Tissue repair peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Tissue repair peptides |
| CAS registry number | 885340-08-9[1] |
| PubChem CID | 62707662[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C38H68N10O14[1] |
| Molecular weight | 889 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
TB-500 is described in a 2012 Journal of Chromatography A doping-control paper as a synthetic version of an active region of thymosin beta 4, and a 2012 Drug Testing and Analysis paper reports the synthesis and characterisation of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in material sold as TB-500. It is therefore a fragment of thymosin beta 4 rather than the full 43-residue peptide, and the two have separate pages here.
Most of the retrieved literature is analytical and anti-doping work: a 2017 Analytical Biochemistry paper on adsorption effects of doping-relevant peptides, a 2023 Drug Testing and Analysis paper on misbranded and adulterated products sold as TB500, TB1000 and SGF1000, and a 2024 Journal of Chromatography B paper on quantification of TB-500 and its metabolites in vitro and in rats. Two recent records are preclinical: a 2026 Joint Diseases and Related Surgery histopathological and biomechanical study of BPC-157 and TB-500 in a rat Achilles tendon model, and a 2025 ACS Applied Materials and Interfaces paper on a TB500 peptide hydrogel in a corneal injury model.
[3, 4, 5, 6, 7, 8, 9]Reported mechanism
A synthetic fragment of thymosin beta 4; the retrieved records characterise the material rather than report a mechanism of its own, so the actin-sequestering mechanism belongs to the parent peptide.
[3, 4]Stated in the titles of the cited 2012 Journal of Chromatography A and 2012 Drug Testing and Analysis papers.
Targets named in the cited records: thymosin beta 4 active region.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
TB-500 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- TB500
- thymosin beta 4 fragment 17-23
- Ac-LKKTETQ
Where this page sits
Research records
Cited research records for TB-500, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include TB-500
Compounds indexed next to it
- Thymosin beta 4 — Tissue repair peptides
- BPC-157 — Tissue repair peptides
Named targets in the cited records
Class page: Tissue repair peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for TB-500?
TB-500 is described in a 2012 Journal of Chromatography A doping-control paper as a synthetic version of an active region of thymosin beta 4, and a 2012 Drug Testing and Analysis paper reports the synthesis and characterisation of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in material sold as TB-500. It is therefore a fragment of thymosin beta 4 rather than the full 43-residue peptide, and the two have separate pages here.
Which class is TB-500 indexed under?
TB-500 is indexed under Tissue repair peptides. This grouping covers peptides whose retrieved research literature is predominantly concerned with tissue repair endpoints in laboratory and animal models, rather than a single shared receptor.
What does the FDA application register show for TB-500?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 62707662, Unii-qhk6Z47gtg. PubChem, National Library of Medicine (2026). pubchem:62707662
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tb-500
- Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of chromatography. A (2012). pmid:23084823
- Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug testing and analysis (2012). pmid:22962027
- Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Analytical biochemistry (2017). pmid:28887173
- TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug testing and analysis (2023). pmid:36482504
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2024). pmid:38382158
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery (2026). pmid:42542926
- Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel. ACS applied materials & interfaces (2025). pmid:41359360
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.